AstraZeneca (AZN) Given "Hold" Rating at Shore Capital

Galtero Lara
Enero 21, 2018

AstraZeneca (LON:AZN) received a GBX 5,500 ($74.59) target price from research analysts at JPMorgan Chase & a report issued on Thursday, January 4th.

Several other research firms have also issued reports on AZN. Deutsche Bank restated a buy rating and set a GBX 5,600 ($75.94) price target on shares of AstraZeneca in a report on Wednesday, October 11th. Deutsche Bank AG restated a "buy" rating and set a GBX 5,500 ($71.65) target price on shares of AstraZeneca plc in a research report on Friday, April 7th. Credit Suisse Group upgraded shares of AstraZeneca from a neutral rating to an outperform rating and lifted their price target for the company from GBX 4,800 ($65.09) to GBX 5,800 ($78.65) in a research report on Monday, October 16th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have issued a buy rating to the stock. AstraZeneca presently has an average rating of "Hold" and a consensus target price of GBX 5,219 ($70.78).

AstraZeneca (LON AZN) traded up GBX 62.50 ($0.85) during mid-day trading on Friday, hitting GBX 5,043 ($68.39). Based on an average daily volume of 3,174,072 shares, the short-interest ratio is now 2.7 days. AstraZeneca has a 52 week low of GBX 4,136.50 ($56.10) and a 52 week high of GBX 5,520 ($74.86). The stock has a market cap of $88,812.73, a PE ratio of 12.70, a PEG ratio of 2.59 and a beta of 0.72.

More news: Inter Milan confident they've snared Daniel Sturridge

AstraZeneca (NYSE:AZN) last posted its quarterly earnings data on Thursday, November 9th. The business had revenue of $6.23 billion for the quarter, compared to analyst estimates of $6 billion. WFG Advisors LP raised its holdings in AstraZeneca by 36.0% in the 2nd quarter. Zions Bancorporation now owns 38,852 shares of the company's stock worth $1,317,000 after buying an additional 37,474 shares in the last quarter. AstraZeneca had a return on equity of 34.02% and a net margin of 15.90%. During the same period in the prior year, the business posted $1.32 EPS. Point72 Asset Management L.P. boosted its holdings in AstraZeneca by 103.1% during the third quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company's stock worth $145,000 after purchasing an additional 1,769 shares in the last quarter. Wealthcare Advisory Partners LLC bought a new position in AstraZeneca in the 3rd quarter valued at about $184,000.

WARNING: "AstraZeneca (AZN) Lifted to Overweight at JPMorgan Chase & Co." was published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and global copyright & trademark law. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Otros informes por

Discuta este artículo